BioStone > Veterinary Biologics and Vaccine Solutions

Veterinary Biologics and Vaccine Solutions

BioStone Animal Health’s acquisition of American Animal Health (AAH) assets and USDA-licensed facility has expanded BioStone’s capabilities in veterinary biologics manufacturing.

Built on AAH’s 40-year legacy of supporting livestock producers through commercial bacterin-toxoids and autogenous bacterins, BioStone is continuing that tradition through USDA-authorized biologics manufacturing and development.

Our current focus includes autogenous bacterin manufacturing services, Mannheimia haemolytica (MH) bacterin-toxoid opportunities, vaccine diluent partnership programs, vaccine antigens and biologics components, and Mycoplasma bovis vaccine programs.

BioStone is actively seeking veterinary partners, distributors, and vaccine manufacturing collaborators to expand access to innovative biologics solutions.